Whether Regorafenib Is Becoming More Tolerable For mCRC Patients

Whether Regorafenib Is Becoming More Tolerable For mCRC Patients

obr

1 year
63 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Whether Regorafenib Is Becoming More Tolerable For mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com
Up Next Autoplay